Werewolf Therapeutics, Inc. HOWL PHARMA
Company Overview
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. In addition, it develops WTX-1011, a conditionally activated INDUCER T cell engager molecule that targets STEAP 1 for prostate cancer, as well as WTX-2022 that targets CDH6 for ovarian and kidney cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
Why Investors Should Care
Operating margin of 40.7% supports profitability.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -27.41% |
| 6 Months: | +33.70% |
| 3 Months: | +156.54% |
| 1 Month: | +146.85% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)77.02 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 55.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 77 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | HOWL Werewolf Therapeutics, Inc. PHARMA | 0.98 | -1.34 | $47.63M | 0.00% | - | -119.86% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -3.89M | -5.07M | -6.05M | -7.45M | -10.96M | -13.79M | -15.37M | -14.97M | -12.54M | -12.22M | -6.07M | -9.25M | -17.16M | -18.96M | -17.12M | -17.99M | -17.54M | -15.73M | -13.27M | 7.16M |
| Net Income | -3.83M | 2.26M | -6.07M | -7.43M | -10.92M | -13.76M | -15.34M | -14.59M | -11.94M | -11.98M | -5.10M | -8.29M | -16.19M | -17.25M | -16.67M | -18.09M | -17.98M | -16.37M | -13.53M | 3.67M |
| Diluted EPS | -4.58 | 0.22 | -6.61 | -83.36 | -3.82 | -0.51 | -0.56 | -0.53 | -0.40 | -0.34 | -0.14 | -0.23 | -0.39 | -0.43 | -0.38 | -0.40 | -0.40 | -0.36 | -0.28 | 0.08 |
| R&D Expense | 2.76M | 3.78M | 4.81M | 4.82M | 7.26M | 9.79M | 10.95M | 13.89M | 13.07M | 11.71M | 9.58M | 10.84M | 12.91M | 15.27M | 12.53M | 13.12M | 13.14M | 11.63M | 8.18M | 6.16M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Income | -22.40M | -50.09M | -56.06M | -40.50M | -73.59M | -60.68M |
| Net Income | -15.04M | -49.98M | -53.81M | -37.37M | -70.52M | -60.82M |
| Diluted EPS | -28.08 | -10.94 | -1.86 | -1.05 | -1.63 | -1.33 |
| R&D Expense | 16.64M | 35.27M | 53.76M | 41.78M | 56.43M | 44.83M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 96.40M | 179.25M | 160.25M | 174.83M | 126.93M | 69.40M |
| Total Equity | -24.30M | -51.86M | 152.79M | 122.34M | 111.37M | 73.39M | 24.80M |
| Cash & Equivalents | - | 92.57M | 157.53M | 129.31M | 134.34M | 111.00M | 57.05M |
| Long Term Debt | - | - | - | - | 40.00M | 32.09M | 32.09M |
| Total Liabilities | - | 7.18M | 26.46M | 37.91M | 63.46M | 53.54M | 44.59M |
| Current Liabilities | - | 5.28M | 11.87M | 23.99M | 19.38M | 15.18M | 36.15M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -18.62M | -42.88M | -40.60M | -32.61M | -56.19M | -60.29M |
| Investing Cash Flow | -560.00K | -498.00K | -3.61M | -769.00K | -254.00K | 0 |
| Financing Cash Flow | 93.86M | 109.43M | 15.91M | 58.43M | 13.08M | 6.03M |
| Capital Expenditure | -560.00K | -498.00K | -3.61M | -769.00K | -254.00K | -0 |
| Free Cash Flow | -19.18M | -43.37M | -44.21M | -33.38M | -56.44M | -60.29M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 29.0% | -32.7% | -44.0% | -33.6% | -96.1% | -245.2% |
| ROCE % | -24.6% | -29.9% | -41.1% | -26.1% | -65.9% | -182.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | RA Capital Management, L.P. | 4.91% | 2.39M | $2.30M |
| 2 | Balyasny Asset Management LP | 3.68% | 1.79M | $1.73M |
| 3 | Vanguard Capital Management LLC | 2.51% | 1.22M | $1.18M |
| 4 | Renaissance Technologies, LLC | 1.39% | 674.63K | $651.02K |
| 5 | Lynx1 Capital Management Lp | 1.35% | 657.79K | $634.76K |
| 6 | Sphera Funds Management Ltd. | 1.29% | 626.81K | $604.87K |
| 7 | DC Funds, LP | 1.21% | 589.10K | $568.48K |
| 8 | Verdad Advisers, LP | 0.72% | 348.71K | $336.50K |
| 9 | Geode Capital Management, LLC | 0.69% | 335.81K | $324.06K |
| 10 | Bank of America Corporation | 0.64% | 311.50K | $300.60K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HOWL
Little-Known HOWL Stock Skyrockets 100% on Biotech Merger News - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxOeV96YUtDdk5XWFhZNVZWMFNDOTlLRXRURlFWckE3MjVBTk9McVdsV2NvX3JtblhENU1CT1FmRUtpdFA0NzJHUUJOeUhOZUxFcTY5T0JKazd2di1jMmhFZnVPaE42N3dyRmhfT1Y2R25Ha3FyN0FZeENoT0VRZ2xUdlN2aWpNeGtzWlJobG…
Werewolf Therapeutics Stock Price Forecast. Should You Buy HOWL? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTFB2WkRaMUZYV3lhU2kzQ1FsTDh1WjNxT2JNOHdTX2hVemFYaU53bXBzbHhXcjMyZF9UNUFxME1PZjkyV0NTbzQ4TA?oc=5" target="_blank">Werewolf Therapeutics Stock Price Forecast. Should You Buy HOWL?</a>&…
HOWL Stock Alert: Halper Sadeh LLC is Investigating Whether Werewolf Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders - The Daily Tribune News
<a href="https://news.google.com/rss/articles/CBMitAJBVV95cUxNZjJpNWFMcUpvejRiVGpEVzZKdUs5V2UySkMtTXE3OW9wakl6Z2RqUmV1QmFKQkk0R3NIcExQbV9faWdhSFhZUXJPRUdFU3NHbUZZa1cwY3hKVUdwY012RFMyeDBWUnJDcTE2VmRoMFpBUDJnNUxQLTl6bmJIMHUySXcwaGpSbGNOM0tiT1…
Werewolf Therapeutics stock soars on Ambros merger deal and $150 million PIPE - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxOekJ3MGZrZ3FtRDdxRldXUGd0TDZCMFlZWUdjZDRuWEwwUWotZk11OUFVcFJlVXJhSVdsUHB5U3hjRXM5THJ6UWM2ODM1MzZ2ck1SczlCZEo3aWdzcGxKVUhfYXpaX3U3a3JtSTJ2V3BPTWY5WXA2ZEVhM3hpaGUwckpSa094SE4zTjZmSF…
HOWL Stock Jumps As One-Off Deal Reshapes Outlook - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxPeWc4VFN6TktSYnF2M1lBRFdZX25mWUFzWHVxaE5iLVRWUWxfNVVwY2N4YUFPV1Ywb3BpZUJ4enZsM0hFTjJWSGllZEVHOGVMalZXOFJtam01TTl3ampxVmRwYkctN2lMVE1yVkpCNkJlM09SX01nSmRsXzdUbkRLVkFDeWE?oc=5" targ…
Werewolf Therapeutics stock soars 120% on Ambros merger deal - Investing.com
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPTEdWTlkyckk2c1d6UFdidnNuYjF1MkRVVGdsc2UyS292M0Ria3p4VUt4RGs3UHVtRFlDZTdwc1JPS0JwSmp5dk14Uk9qVzNWak1HVXo1Z2MzdHNwa3RLaGJyMF9oTVl5bGlXQkI5M0hZVnRzdnlYN0sxTEZUcmw1bklqVXdLN01BNEJjcH…
HOWL — Frequently Asked Questions
What is the current share price of Werewolf Therapeutics, Inc. (HOWL)?
As of 2026-09-19 21:16 PDT, Werewolf Therapeutics, Inc. (HOWL) trades at $0.98 on NasdaqCM. Its 52-week range is $0.31 to $2.19.
What is the market capitalisation of HOWL?
Werewolf Therapeutics, Inc. (HOWL) has a market capitalisation of $47.63M on NasdaqCM.
What is the P/E ratio of HOWL?
HOWL trades at a trailing price-to-earnings (P/E) ratio of -1.34. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.88.
What is the return on equity (ROE) of HOWL?
HOWL has a return on equity (ROE) of -119.86%.
Is HOWL a good stock to buy?
This page provides a data-driven analysis of Werewolf Therapeutics, Inc. (HOWL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.